GlaxoSmithKline’s $85 million deal with Surface Oncology caps off a big month for NK cell technologies and adds PVRIG to the growing list of NK cell checkpoint targets entering pharma pipelines. ...
Cadent’s neuropsychiatry portfolio gives Novartis clinical programs in an area that the pharma has been eyeing for business development opportunities. Novartis AG (NYSE:NVS; SIX:NOVN) will acquire Cadent Therapeutics Inc. for $210 million up front and...
Cancer screening play Singlera raises megaroundSinglera Genomics Inc. raised $150 million in a series B round led by the CICC Kai Tak Innovative Biomedicine Fund, and co-led by Detong Capital and Furong Investment. Fellow new...
Four months after Jyseleca’s surprise setback at FDA, Gilead and Galapagos are abandoning U.S. development of the therapy that was once the centerpiece of a $5 billion deal between the companies. ...
In Prevail, Lilly found an M&A target with expertise in one of its core areas — neuroscience — that can also be a building block around which it expects to amass a gene therapy pipeline via more...
Allogene has found its gateway to China via a deal with Hillhouse-backed Overland that gives the newly launched China company its second partner and an allogeneic CAR T cell platform. The news came...
AstraZeneca’s planned $39.4 billion takeout of Alexion gives the biotech’s shareholders an exit from a stock that’s largely been tracking sideways for years despite topline growth, and provides the pharma...
With a pipeline heavy on line extensions and its bestseller headed toward a patent cliff, new Ipsen CEO David Loew is doubling down on the mid-cap biopharma’s commitment to external innovation. But...
Near the end of a year when most of Gilead’s over $30 billion in deals were in cancer, the company’s latest billion-dollar acquisition showed an appetite for growth in its area of greatest historical strength:...
Weeks after Merck & Co.’s multibillion dollar takeout of VelosBio, Boehringer believes its purchase of NBE in a smaller deal will give it an earlier-stage, best-in-class product against the same target. Boehringer Ingelheim GmbH will acquire...
Sino Biopharm buys $515M stake in SinovacSino Biopharmaceutical Ltd. (HKEX:1177) paid $515 million for a 15% stake in Sinovac Biotech Ltd. (NASDAQ:SVA). The proceeds will fund development and production capacity expansion for Sinovac's Phase III-stage...
Via a deal with Atara, Bayer’s latest additions to its new gene and cell therapy unit are an allogeneic CAR T treatment that the pharma hopes can treat solid tumors — and an autologous version that...
Artios’ deal with German pharma Merck represents the latest vote of confidence in the DNA damage repair sector, and extends the privately held biotech’s cash runway as it prepares for its first clinical trials. For its...
An investor syndicate is backing Viracta with $105 million in fresh capital as the biotech goes public via a reverse merger and plans a pivotal trial of its lead therapy targeting EBV-positive lymphomas. By merging...
Biogen is paying Sage $1.5 billion up front to gain rights to two late-stage CNS products, bolstering the company’s pipeline as it approaches one of the biggest binary decisions in recent industry...
